Showing results (121-130 of 166) with videos related to

Sort By:
Pageof 17
Leukemia & Lymphoma|July 9, 2025
Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trialKoji Izutsu, Daigo Akahane, Tomomi Toubai, et al.
International Journal of Hematology|January 18, 2026
Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3Koji Izutsu, Daigo Akahane, Tomomi Toubai, et al.
Cancer Science|May 14, 2025
PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular LymphomaNoriko Fukuhara, Isao Yoshida, Takuro Ishiguro, et al.
Cancer Science|May 13, 2014
Clonal heterogeneity of lymphoid malignancies correlates with poor prognosisMiyuki Suguro, Noriaki Yoshida, Akira Umino, et al.
Cancer Science|October 9, 2021
HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1)Masaki Ri, Shinsuke Iida, Dai Maruyama, et al.
International Journal of Clinical Oncology|April 18, 2023
Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in JapanHideki Goto, Toshio Kitawaki, Nobuharu Fujii, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2011
Favorable outcome of unrelated cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemiaYasushi Onishi, Osamu Sasaki, Satoshi Ichikawa, et al.
Blood Advances|October 7, 2025
Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignanciesHisayuki Yokoyama, Noriko Fukuhara, Koji Ando, et al.
Leukemia|February 17, 2025
Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next studyAyumi Fujimoto, Kana Miyazaki, Kimikazu Yakushijin, et al.
British Journal of Haematology|January 8, 2025
A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 studyWataru Munakata, Takahiro Kumode, Hideki Goto, et al.
Pageof 17